Pfizer and Valneva Join Forces on Lyme Disease Vaccine

Lyme disease vaccine induces antibodies in Phase II clinical trial. SHORT SUMMARY: The engineered protein vaccine VLA15 induces multiple antibodies in a Phase II trial and has the potential to provide protection against the different bacteria that cause Lyme disease in North America and Europe. Lyme disease is caused by bacteria (Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii) that are delivered by a bite from an infected tick. Although antibiotics can treat Lyme disease, some people do not realize they have been infected. The longer a person waits to receive treatment, the worse the outcome is likely to be. Thus, an…...